List of Excipients in Branded Drug ALBENZA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Amneal Pharmaceuticals LLC	ALBENZA	albendazole	64896-693	CARNAUBA WAX
Amneal Pharmaceuticals LLC	ALBENZA	albendazole	64896-693	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals LLC	ALBENZA	albendazole	64896-693	HYPROMELLOSES
Amneal Pharmaceuticals LLC	ALBENZA	albendazole	64896-693	LACTOSE MONOHYDRATE

Albenza Excipient Strategy and Commercial Opportunities for Albendazole

Last updated: August 3, 2026

Albenza is a 200 mg albendazole chewable tablet with an old, largely unprotected active ingredient and a formulation profile that creates commercial opportunities in taste masking, pediatric delivery, dissolution enhancement, and global supply. The principal opportunity is not blocking generic tablets through legacy composition claims. It is developing differentiated dosage forms that improve administration, bioavailability, stability, or access while avoiding unnecessary regulatory and manufacturing complexity.

What is Albenza and what is its FDA status?

Albenza is the U.S. brand name for albendazole, a benzimidazole anthelmintic used for neurocysticercosis and hydatid disease. The FDA approved Albenza under NDA 020666 in 1996. The product is supplied as a 200 mg chewable tablet and is administered orally. The prescribing information recommends administration with food, particularly a fatty meal, to increase systemic exposure [1].

Attribute	Albenza
Active ingredient	Albendazole
Strength	200 mg
Dosage form	Chewable tablet
U.S. approval	1996
FDA pathway	NDA 020666
Primary labeled uses	Neurocysticercosis and hydatid disease
Pharmacologic class	Benzimidazole anthelmintic
Key absorption issue	Poor aqueous solubility and variable oral absorption
Food effect	High-fat food materially increases exposure
Prescription status	Prescription drug in the United States

Albendazole is practically insoluble in water. Its low and variable absorption limits systemic exposure and makes formulation performance commercially relevant. Food-dependent administration also creates an opportunity for products that deliver more consistent exposure with less reliance on meal composition [1,2].

What excipients are used in Albenza tablets?

The Albenza 200 mg chewable tablet uses a conventional direct-compression excipient system with binders, disintegrants, lubricants, fillers, surfactants, sweeteners, flavors, and processing aids.

The inactive ingredients identified in the product labeling include colloidal silicon dioxide, corn starch, croscarmellose sodium, flavoring, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulfate, sodium saccharin, and talc [1].

Excipient	Likely formulation function	Commercial relevance
Lactose monohydrate	Diluent and filler	Creates a milk-sugar exposure issue for some patients; may be replaced in lactose-free products
Microcrystalline cellulose	Filler and compression aid	Supports tablet hardness and dose uniformity
Corn starch	Filler and disintegrant	Low-cost, familiar excipient; may contribute to regional supply-chain constraints
Croscarmellose sodium	Superdisintegrant	Supports tablet breakup after chewing or swallowing
Povidone	Binder	Helps maintain tablet integrity at high active loading
Sodium lauryl sulfate	Wetting agent and surfactant	May improve albendazole wetting but can affect taste and gastrointestinal tolerability
Magnesium stearate	Lubricant	Excessive use can slow wetting and dissolution
Colloidal silicon dioxide	Glidant and moisture-control aid	Supports powder flow and manufacturing consistency
Sodium saccharin	Sweetener	Supports palatability but has a distinctive aftertaste
Flavoring	Taste masking	Central to pediatric acceptance
Talc	Processing aid and anti-adherent	Requires tight control of quality and regulatory specifications

Albenza’s excipient system is functional but not highly differentiated. The presence of lactose, sodium lauryl sulfate, saccharin, and conventional flavoring creates room for alternative compositions aimed at improved tolerability, taste, excipient exclusion, or pediatric use.

Which excipient attributes create the largest commercial opportunity?

The highest-value targets are taste, dissolution, food independence, and pediatric administration.

Taste masking and pediatric acceptability

Albendazole is a high-dose, poorly soluble drug with an unpleasant taste profile. A 200 mg tablet can be difficult for children to chew or swallow. Conventional sweeteners and flavors may reduce initial bitterness but often do not control the persistent aftertaste associated with the active ingredient and surfactant system.

Potential approaches include:

• Polymer coating of albendazole particles.
• Ion-exchange or complexation systems where technically suitable.
• Lipid-based taste-masking matrices.
• Spray-dried dispersions with selected polymers.
• Multiparticulate granules or mini-tablets incorporated into a pleasant vehicle.
• Dual-flavor systems that suppress bitterness and aftertaste.
• Sugar-free chewable formulations using polyols and high-intensity sweeteners.

The strongest commercial formulation would combine taste masking with rapid disintegration and a low pill burden. Taste masking alone may support an incremental product, but taste masking plus improved exposure has stronger differentiation potential.

Dissolution enhancement

Albendazole’s poor aqueous solubility is a recognized formulation barrier. Candidate excipient strategies include:

• Surfactant-assisted wetting.
• Amorphous solid dispersions using polymers such as copovidone, PVP, or selected cellulose derivatives.
• Spray drying or hot-melt extrusion.
• Nanocrystal or micronized suspensions.
• Lipid-based formulations.
• Self-emulsifying drug-delivery systems.
• Cyclodextrin or other complexation approaches, subject to dose and safety constraints.

A formulation should be evaluated against the existing food effect rather than only against a standard tablet dissolution profile. A product that improves dissolution in vitro but remains highly food dependent may have limited clinical or commercial value.

Lactose-free and excipient-reduced products

The labeled lactose content creates a straightforward opportunity for a lactose-free version. Replacement options include mannitol, sorbitol, isomalt, microcrystalline cellulose, calcium phosphate, or suitable co-processed excipients.

A lactose-free product could be positioned for:

• Pediatric patients with lactose intolerance concerns.
• Hospital formularies seeking a simpler excipient profile.
• International markets with different labeling expectations.
• Procurement systems requiring allergen or dietary exclusions.

The commercial benefit is likely incremental rather than transformative unless the product also improves taste, stability, or dissolution.

Sugar-free delivery

A sugar-free chewable formulation could use mannitol, xylitol, erythritol, sucralose, acesulfame potassium, or combinations of polyols and high-intensity sweeteners. Polyols can create cooling effects, hygroscopicity, and gastrointestinal tolerance issues. The formulation must balance compression, mouthfeel, moisture control, and taste persistence.

A sugar-free product may have value in institutional, pediatric, and chronic-treatment settings, but the target indications for Albenza often involve defined treatment courses rather than long-term daily use. The pricing premium therefore depends on payer acceptance and measurable administration benefits.

What formulations are protected by Albenza or albendazole patents?

The core albendazole compound is an old small molecule. Conventional albendazole tablets face limited composition-of-matter protection because the active ingredient was disclosed and commercialized decades ago.

The FDA Orange Book listing for NDA 020666 is the relevant U.S. source for patents that may be listed against the reference product. Public FDA records do not indicate a meaningful current listed-patent barrier that would prevent approval of a conventional albendazole tablet generic [3].

Protection category	Current commercial assessment
Albendazole compound patent	Expired or commercially irrelevant
Original Albenza tablet protection	Expired
Conventional 200 mg tablet	Generally exposed to generic competition
New taste-masked composition	Potentially patentable if novel and nonobvious
Improved dissolution system	Potentially patentable
Pediatric suspension or ODT	Potentially patentable as a composition or formulation
Manufacturing process	Potentially patentable if it produces a distinct technical result
New method of use	Potentially patentable only for a genuinely novel, nonobvious indication or regimen
Device or packaging system	Potentially protectable separately from the drug formulation

A formulation patent should claim measurable technical advantages, such as improved dissolution, reduced food effect, enhanced stability, acceptable taste scores, reduced degradation, or improved dose uniformity. Broad claims that merely substitute one conventional filler for another are vulnerable to validity and obviousness challenges.

When does Albenza lose exclusivity?

Albenza’s primary U.S. market exclusivity has already expired. The 1996 approval date means the product is outside the normal five-year new chemical entity exclusivity period and the three-year exclusivity period associated with qualifying new clinical investigations [4].

Exclusivity type	Albenza position
New chemical entity exclusivity	Expired
Three-year clinical-investigation exclusivity	Expired
Orphan-drug exclusivity	No current commercial relevance identified for the reference product
Pediatric exclusivity	No current blocking effect
Listed patent exclusivity	No material active barrier identified in public FDA records
Generic entry status	Open to approved generic competition, subject to ANDA requirements

The principal barriers for generic entrants are therefore regulatory, technical, and commercial rather than patent-based. These include product-quality requirements, bioequivalence strategy, supply reliability, active pharmaceutical ingredient sourcing, and the ability to maintain acceptable chewable-tablet performance.

How many patents cover Albenza and albendazole formulations?

No meaningful active patent estate appears to cover the original Albenza 200 mg chewable tablet as a product. Separate third-party patents may cover particular albendazole delivery technologies, but those rights would need to be assessed claim by claim and jurisdiction by jurisdiction.

A company developing a new albendazole product should search at least four patent groups:

1. Albendazole solid dispersions and amorphous compositions.
2. Nanoparticles, nanosuspensions, and lipid-based delivery systems.
3. Pediatric chewables, orally disintegrating tablets, and oral suspensions.
4. Combination products and new antiparasitic treatment regimens.

The relevant freedom-to-operate question is not whether albendazole is patented generally. It is whether a proposed particle-size range, polymer system, manufacturing process, dosing regimen, or delivery platform falls within an enforceable third-party claim.

What Paragraph IV challenges and litigation affect Albenza?

Because the core Albenza patent position is old and the reference product has no apparent active Orange Book patent barrier of commercial significance, Paragraph IV litigation is not the central risk for a standard albendazole tablet program.

A generic applicant could pursue an ANDA using the applicable FDA pathway and address any listed patent certifications in the reference-product record. The main litigation risks would arise if a new branded formulation is approved with later-listed patents covering:

• A specific taste-masking matrix.
• A particle-size distribution.
• A stabilized amorphous form.
• A lipid or self-emulsifying system.
• A pediatric dosage form.
• A new method of treatment.

No major current settlement agreement affecting conventional albendazole tablet entry is identified in the public FDA and widely reported patent records reviewed for this assessment. New product sponsors should monitor Orange Book updates, ANDA litigation dockets, and patent filings tied to differentiated albendazole formulations.

What FDA pathways are available for an albendazole formulation?

The pathway depends on whether the product is therapeutically equivalent to Albenza or materially different.

Abbreviated New Drug Application

An ANDA is the most direct route for a conventional albendazole tablet that matches the reference product in active ingredient, dosage form, strength, route, and relevant performance characteristics. The applicant must address pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and any applicable patent certifications [5].

This route is appropriate for low-cost generic tablets but offers limited protection against price competition.

505(b)(2) application

A 505(b)(2) application may be more suitable for a new suspension, orally disintegrating tablet, modified-release system, or formulation with a different clinical profile. The sponsor can rely partly on FDA findings for an approved albendazole product while supplying additional data needed for the proposed formulation [6].

Potential 505(b)(2) differentiation includes:

• Reduced food effect.
• Improved pediatric dosing.
• Better palatability.
• Improved systemic exposure.
• Lower administration burden.
• More consistent absorption in patients unable to consume a high-fat meal.

The sponsor must establish that the formulation change is clinically and technically meaningful. A minor excipient substitution may not justify the cost of a 505(b)(2) program.

New drug application

A full NDA would be relevant if the sponsor pursues a new indication, a substantial clinical benefit, or a product that cannot rely sufficiently on the existing albendazole safety and efficacy record. This is the most expensive route and is unlikely to be justified for excipient optimization alone.

What generic entry risks exist for Albenza?

Generic entry risk is high for the conventional 200 mg tablet. The absence of a material active patent barrier allows multiple manufacturers to compete if they can satisfy FDA requirements and maintain supply.

The commercial risks are:

• Price erosion in the standard tablet segment.
• Substitution by generic albendazole products.
• Limited prescriber loyalty to the Albenza brand.
• Procurement pressure from hospitals and public-health buyers.
• API and excipient supply disruptions.
• Difficulty supporting a premium without a measurable clinical or administration benefit.

The branded product can retain value through differentiated delivery rather than through legacy brand recognition. A pediatric-friendly product, a stable oral suspension, or a formulation with reduced food dependence could occupy a less commoditized segment.

What licensing deals and commercial partnerships are available?

Albendazole has relevance to public-health programs, antiparasitic campaigns, hospitals, pharmacies, and international procurement systems. Potential licensing structures include:

• Regional rights for pediatric or suspension formulations.
• Manufacturing licenses for low-cost chewable tablets.
• Co-development agreements for amorphous dispersions or nanosuspensions.
• Supply agreements with public-health procurement organizations.
• Technology licenses for taste-masking platforms.
• Contract manufacturing arrangements using local packaging or tableting capacity.

The most defensible licensing asset would be a formulation platform with demonstrated performance across multiple markets. A simple excipient substitution is less attractive to a licensee because it is easier to design around and may not support premium pricing.

How strong is the patent estate for a new albendazole product?

A new albendazole product can have a moderate patent position if the claims capture a specific composition and a measurable performance advantage. Patent strength will be weak where the claims rely on routine excipient selection without unexpected results.

The strongest claim architecture would combine:

• A defined albendazole particle-size or solid-state profile.
• A specific polymer, surfactant, or lipid ratio.
• A manufacturing process that produces the claimed structure.
• Dissolution or exposure data showing an advantage.
• Taste, stability, or food-effect data.
• A dosage-form claim directed to pediatric administration.

Process claims can add protection, but they may be difficult to detect in finished-product markets. Formulation claims are more commercially useful when the product can be identified through public testing or regulatory records.

What is the best excipient strategy for commercial development?

The preferred strategy is a two-track program.

Track one: low-cost generic substitution

Develop a lactose-free, sugar-free 200 mg chewable tablet using conventional excipients and a robust taste-masking system. The target is a reliable ANDA product with low manufacturing complexity and broad geographic suitability.

Track two: differentiated 505(b)(2) product

Develop a pediatric oral suspension, orally disintegrating tablet, or multiparticulate product using a dissolution-enhancing and taste-masking platform. The target product should show at least one of the following:

• Reduced dependence on high-fat meals.
• Higher or more consistent exposure.
• Better palatability.
• Flexible weight-based dosing.
• Longer in-use stability.
• Reduced dosing errors.
• Improved acceptability for children.

The second track offers stronger intellectual-property and licensing potential but requires clinical, food-effect, stability, and palatability investment.

Key Takeaways

• Albenza is a 200 mg albendazole chewable tablet approved in the United States in 1996.
• The original product has no meaningful remaining exclusivity barrier for conventional generic entry.
• The labeled excipient system includes lactose, corn starch, croscarmellose sodium, povidone, sodium lauryl sulfate, sodium saccharin, flavoring, and standard compression aids.
• The best formulation opportunities are taste masking, dissolution enhancement, food-effect reduction, lactose-free delivery, and pediatric dosing.
• A conventional tablet is most suitable for an ANDA strategy and will face high price competition.
• A differentiated suspension, orally disintegrating tablet, or multiparticulate formulation may support a 505(b)(2) strategy.
• New patent value will depend on a specific formulation architecture supported by unexpected technical data.
• The commercial opportunity is stronger in pediatric, public-health, hospital, and international procurement channels than in an undifferentiated adult tablet market.
• Standard albendazole tablet development faces generic competition rather than a major patent-litigation barrier.

FAQs

Can albendazole be formulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, calcium phosphate, isomalt, or other suitable fillers. The replacement must preserve tablet hardness, disintegration, taste, stability, and bioavailability.

Is albendazole suitable for an orally disintegrating tablet?

Potentially, but the 200 mg dose and poor solubility create formulation challenges. Particle engineering, taste masking, superdisintegrants, and a low-residue mouthfeel would be needed.

Can a new albendazole suspension receive new market exclusivity?

A suspension may qualify for formulation-related patent protection and, depending on the regulatory and clinical program, potentially 505(b)(2)-based exclusivity. Exclusivity would depend on the specific approval and supporting clinical investigations.

What excipient should be prioritized for albendazole dissolution enhancement?

No single excipient is universally optimal. Surfactants, polymers, lipid systems, and particle-engineering technologies should be screened together because improved wetting, solid-state stability, taste, and gastrointestinal tolerability must be balanced.

Is albendazole a good candidate for a public-health-focused formulation?

Yes. A stable, low-cost, pediatric-friendly formulation with flexible dosing and reduced food dependence could address procurement and administration needs in institutional and international settings.

References

1. U.S. Food and Drug Administration. (2023). Albenza (albendazole) tablets, chewable: Prescribing information.
2. DrugBank. (n.d.). Albendazole: Drug information and pharmacology.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). New drug product exclusivity.
5. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format.
6. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2).
7. World Health Organization. (2023). WHO guideline for preventive chemotherapy for neglected tropical diseases.